Horizon Pharma PLC (NASDAQ:HZNP) had its price objective upped by analysts at Jefferies Group LLC from $16.00 to $21.00 in a research note issued on Tuesday, November 7th. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Jefferies Group LLC’s price target would suggest a potential upside of 53.73% from the company’s current price. Jefferies Group also issued estimates for Horizon Pharma PLC’s Q4 2017 earnings at $0.22 EPS, FY2017 earnings at $0.71 EPS, FY2018 earnings at $1.04 EPS, FY2019 earnings at $1.17 EPS, FY2020 earnings at $1.43 EPS and FY2021 earnings at $1.73 EPS.
HZNP has been the topic of several other reports. Piper Jaffray Companies set a $17.00 target price on Horizon Pharma PLC and gave the company a “buy” rating in a research note on Tuesday, July 25th. Mizuho reissued a “hold” rating and set a $12.00 target price (up from $9.00) on shares of Horizon Pharma PLC in a research note on Monday, August 28th. Zacks Investment Research cut Horizon Pharma PLC from a “hold” rating to a “sell” rating in a research note on Tuesday, October 10th. ValuEngine cut Horizon Pharma PLC from a “buy” rating to a “hold” rating in a research note on Friday, September 1st. Finally, UBS AG set a $16.00 target price on Horizon Pharma PLC and gave the stock a “buy” rating in a research note on Tuesday, August 8th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and eleven have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $18.42.
Shares of Horizon Pharma PLC (NASDAQ HZNP) traded up $0.01 during midday trading on Tuesday, hitting $13.66. The stock had a trading volume of 1,143,920 shares, compared to its average volume of 3,493,936. Horizon Pharma PLC has a 52 week low of $9.45 and a 52 week high of $21.98. The company has a quick ratio of 1.52, a current ratio of 1.64 and a debt-to-equity ratio of 1.89. The stock has a market capitalization of $2,240.00, a price-to-earnings ratio of 9.89, a price-to-earnings-growth ratio of 1.16 and a beta of 1.32.
Horizon Pharma PLC (NASDAQ:HZNP) last released its earnings results on Monday, November 6th. The biopharmaceutical company reported $0.26 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.22 by $0.04. Horizon Pharma PLC had a positive return on equity of 20.22% and a negative net margin of 45.28%. The company had revenue of $271.60 million during the quarter, compared to the consensus estimate of $259.74 million. During the same quarter in the previous year, the company posted $0.70 EPS. Horizon Pharma PLC’s quarterly revenue was up 30.1% compared to the same quarter last year. analysts anticipate that Horizon Pharma PLC will post 0.72 EPS for the current year.
COPYRIGHT VIOLATION NOTICE: This piece was originally published by BBNS and is owned by of BBNS. If you are viewing this piece on another website, it was stolen and republished in violation of United States and international trademark and copyright law. The legal version of this piece can be accessed at https://baseballnewssource.com/markets/horizon-pharma-plc-hznp-price-target-raised-to-21-00-at-jefferies-group-llc/1764886.html.
Several large investors have recently bought and sold shares of HZNP. Prudential Financial Inc. lifted its stake in shares of Horizon Pharma PLC by 2.6% during the 1st quarter. Prudential Financial Inc. now owns 16,680 shares of the biopharmaceutical company’s stock worth $247,000 after acquiring an additional 420 shares during the last quarter. Wellington Management Group LLP purchased a new position in shares of Horizon Pharma PLC in the 1st quarter valued at $730,000. Vanguard Group Inc. increased its holdings in shares of Horizon Pharma PLC by 4.1% in the 1st quarter. Vanguard Group Inc. now owns 12,749,275 shares of the biopharmaceutical company’s stock valued at $188,434,000 after acquiring an additional 506,596 shares during the period. Geode Capital Management LLC increased its holdings in shares of Horizon Pharma PLC by 0.7% in the 1st quarter. Geode Capital Management LLC now owns 1,379,581 shares of the biopharmaceutical company’s stock valued at $20,389,000 after acquiring an additional 9,476 shares during the period. Finally, Dimensional Fund Advisors LP increased its holdings in shares of Horizon Pharma PLC by 10.2% in the 1st quarter. Dimensional Fund Advisors LP now owns 2,856,197 shares of the biopharmaceutical company’s stock valued at $42,216,000 after acquiring an additional 264,592 shares during the period. 81.40% of the stock is owned by institutional investors and hedge funds.
About Horizon Pharma PLC
Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.
Receive News & Ratings for Horizon Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma PLC and related companies with our FREE daily email newsletter.